Howard Hochster, MD, regarding the role of genetic testing in mCRC

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisionsПодробнее

Howard Hochster, MD, Explains Colorectal Cancer Screening GuidelinesПодробнее

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRCПодробнее

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancersПодробнее

Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patientsПодробнее

Howard Hochster, MD, on the management of mCRC patients receiving regorafenibПодробнее

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patientsПодробнее

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patientsПодробнее

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRCПодробнее

Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patientsПодробнее

Genetic Testing in Colorectal CancerПодробнее

Expanded RAS Mutation Testing in Metastatic Colorectal CancerПодробнее

Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRCПодробнее

The Role of Genetic TestingПодробнее

Dr. Howard Hochster Discusses Clinical Cancer, Gastrointestinal (GI) Oncology, and Colon CancerПодробнее

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumabПодробнее

The Role of Genetic Testing for Inherited Prostate Cancer RiskПодробнее

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRCПодробнее

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.Подробнее